K
Kudrat Abdulkadyrov
Researcher at Medical University of Lublin
Publications - 49
Citations - 2777
Kudrat Abdulkadyrov is an academic researcher from Medical University of Lublin. The author has contributed to research in topics: Multiple myeloma & Imatinib mesylate. The author has an hindex of 11, co-authored 49 publications receiving 2636 citations.
Papers
More filters
Journal ArticleDOI
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Jesús F. San Miguel,Rudolf Schlag,Nuriet K. Khuageva,Meletios A. Dimopoulos,Ofer Shpilberg,Martin Kropff,Ivan Spicka,Maria Teresa Petrucci,Antonio Palumbo,Olga Samoilova,Anna Dmoszynska,Kudrat Abdulkadyrov,Rik Schots,Bin Jiang,Maria-Victoria Mateos,Kenneth C. Anderson,Dixie Lee Esseltine,Kevin Liu,Andrew Cakana,Helgi van de Velde,Paul G. Richardson +20 more
TL;DR: Bortezomib plus melphalan-prednisone alone in patients with newly diagnosed myeloma who were ineligible for high-dose therapy was superior to melphAlan-predisonsone alone.
Journal ArticleDOI
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Maria-Victoria Mateos,Paul G. Richardson,Rudolf Schlag,Nuriet K. Khuageva,Meletios A. Dimopoulos,Ofer Shpilberg,Martin Kropff,Ivan Spicka,Maria Teresa Petrucci,Antonio Palumbo,Olga Samoilova,Anna Dmoszynska,Kudrat Abdulkadyrov,Rik Schots,Bin Jiang,Dixie Lee Esseltine,Kevin Liu,Andrew Cakana,Helgi van de Velde,Jesús F. San Miguel +19 more
TL;DR: VMP significantly prolongs OS versus MP after lengthy follow-up and extensive subsequent antimyeloma therapy, and appears more beneficial than first treating with conventional agents and saving bortezomib- and other novel agent-based treatment until relapse.
Journal ArticleDOI
Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
Jesús F. San Miguel,Rudolf Schlag,Nuriet K. Khuageva,Meletios A. Dimopoulos,Ofer Shpilberg,Martin Kropff,Ivan Spicka,Maria Teresa Petrucci,Antonio Palumbo,Olga Samoilova,Anna Dmoszynska,Kudrat Abdulkadyrov,Michel Delforge,Bin Jiang,Maria-Victoria Mateos,Kenneth C. Anderson,Dixie-Lee Esseltine,Kevin X. Liu,William Deraedt,Andrew Cakana,Helgi van de Velde,Paul G. Richardson +21 more
TL;DR: VMP resulted in a significant reduction in risk of death versus MP that was maintained after 5 years' follow-up and despite substantial use of novel-agent-based salvage therapies, there is no emerging safety signal for second primary malignancies following VMP.
Journal ArticleDOI
MMY-3002: A Phase 3 Study Comparing Bortezomib-Melphalan-Prednisone (VMP) with Melphalan-Prednisone (MP) in Newly Diagnosed Multiple Myeloma.
J F San Miguel,Rudolf Schlag,Nuriet K. Khuageva,Ofer Shpilberg,M.A. Dimopoulos,Martin Kropff,Ivan Spicka,M.T. Petrucci,Olga Samoilova,Anna Dmoszynska,Kudrat Abdulkadyrov,Rik Schots,Bin Jiang,Antonio Palumbo,M.V. Mateos,Kevin Liu,Andrew Cakana,H van de Velde,P. G. Richardson +18 more
TL;DR: MMY-3002 is a phase 3 study comparing VMP with standard MP in patients with previously untreated MM who are not candidates for high-dose chemotherapy/stem-cell transplant and secondary endpoints included progression-free survival, overall survival (OS), overall response rate, time to and duration of response, and safety.
Journal ArticleDOI
Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia
Jeffrey H. Lipton,Nina Khoroshko,Anatoly Golenkov,Kudrat Abdulkadyrov,Krishnan Nair,D Raghunadharao,Tim H. Brümmendorf,Kisook Yoo,Bengt Bergström +8 more
TL;DR: PEG-IFNα-2a (40 kD), 450 µg once weekly, compared with IFNα -2a, 9 MIU once daily, resulted in higher rates of hematologic and cytogenetic response and greater overall survival, including progression-free survival at the end of treatment and overall survival after 30 months of follow-up.